Abstract： Objective:To explore the relationship between the clinical stage of tumor abnormal protein(TAP), heat shock protein 90α(HSP90α)and double cortin-like kinase 1(DCLK1)expression in non-small cell lung cancer(NSCLC)patients.Methods:This study was a case control study, from January 2020 to January 2022, a total of 72 NSCLC inpatients admitted to the Respiratory Department of Shanxi Cancer Hospital were selected as the NSCLC group, 50 males and 22 females, aged(64.13±10.23)years old, ranging from 51 to 78 years old.At the same time, a total of 50 patients with benign pulmonary diseases excluded from malignant tumors by clinical, imaging and pathological examinations were selected as the benign group, 34 males and 16 females, aged(65.09±10.05)years old, ranging from 48 to 79 years old.The expression levels of TAP, HSP90α and DCLK 1 were measured in the NSCLC group before and after chemotherapy in both groups.TAP and HSP90α were analyzed by receiver operator characteristic(ROC)curve, diagnostic efficacy of DCLK1 single index and combined index in patients with NSCLC, use multiple linear regression analysis to analyze TAP and HSP90α.The correlation between DCLK1 and clinical stage and chemotherapy effect was analyzed, to evaluate the effect of imaging treatment.Results:Before the treatment, the expression levels of TAP[(196.20±20.13)μm 2], HSP90α[(66.35±10.13)μg/L], and DCLK1 [(6.54±2.01)μg/L] in the NSCLC group were higher than those in the benign group[(137.23±10.36)μm 2, (50.22±8.24)μg/L, (2.82±1.37)μg/L], the differences were statistically significant( P<0.05).After the chemotherapy, the expression levels of TAP [(154.23±10.24)μm 2, HSP90α[(55.17±8.09)μg/L] and DCLK 1 [(3.67±1.42)μg/L] in NSCLC patients were lower than those observed before chemotherapy, the differences were statistically significant( P<0.05).The sensitivity, specificity, and accuracy of the combined TAP, HSP90α, and DCLK1 were 100%, 98.0%, and 99.2% respectively, which were higher than each index alone, the difference was statistically significant( P<0.05).ROC curve analysis showed that the area under the curve of TAP, HSP90α, and DCLK 1 were 0.998(95% CI: 0.993 to 1.000), 0.889(95% CI: 0.833 to 0.944), 0.916(95% CI: 0.868 to 0.964), and 0.999(95% CI: 0.997 to 1.000)respectively, the difference was statistically significant( P<0.05).Comparison of tumor staging stageⅢ, ⅣTAP, HSP90α and DCLK 1 levels in NSCLC, the difference was statistically significant( P<0.05).There were correlation among TAP, HSP90α and tumor clinical stage( P<0.05).The results of the multiple linear regression model showed that the TAP, HSP90αand DCLK 1 levels and the effect of chemotherapy treatment were all correlated( P<0.05).After 4 cycles of treatment, 13 patients in the NSCLC group had complete response and 30 partial responses, with a response rate of 59.7%(43/72). Conclusions:TAP, HSP90α and DCLK 1 expression levels in NSCLC patients will decrease after treatment.The sensitivity, specificity and accuracy of the combined detection of the three indexes are higher than that of each index alone, and the levels of TAP, HSP90α and DCLK1 and the clinical stage, and the levels of TAP, HSP90α and DCLK1 and the chemotherapy effect are related, better remission rate in NSCLC patients after chemotherapy.